Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer's disease, restores synapse integrity and memory in a disease mouse model.
Alzheimer's disease
Amyloid plaques
Wnt signaling
cell biology
hAPP-J20
hAPPNL-G-F/NL-G-F
human
mouse
neuroscience
synapse degeneration
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
29 Jan 2024
29 Jan 2024
Historique:
medline:
30
1
2024
pubmed:
29
1
2024
entrez:
29
1
2024
Statut:
epublish
Résumé
Increasing evidence supports a role for deficient Wnt signaling in Alzheimer's disease (AD). Studies reveal that the secreted Wnt antagonist Dickkopf-3 (DKK3) colocalizes to amyloid plaques in AD patients. Here, we investigate the contribution of DKK3 to synapse integrity in healthy and AD brains. Our findings show that DKK3 expression is upregulated in the brains of AD subjects and that DKK3 protein levels increase at early stages in the disease. In hAPP-J20 and hAPP Alzheimer’s disease is the most common form of dementia worldwide. The cognitive decline typically observed in this condition is associated with the weakening and eventually the loss of synapses, the structures that allow neurons to communicate. Increasing evidence points to this deterioration being linked to deficiency in the Wnt signalling pathway, a cascade of molecular events crucial for brain function and development. The DKK protein family helps to tightly regulate the Wnt pathway by dampening its activity. Previous work suggests that DKK proteins could also be connected to Alzheimer’s disease. For example, an elevated amount of DKK1 leads to synapse and memory defects in mice, while brain production of DKK1 is increased in individuals with late Alzheimer’s. More recent studies show high levels of another DKK protein, DKK3, in Alzheimer’s patients. This protein is also present in the harmful amyloid-β aggregates, named ‘plaques’, that typically form in the brain in this condition. Despite these findings, how DKK3 participates in synaptic health remains unclear. To address this question, Martin-Flores, Podpolny et al. tracked DKK3 levels in the brains of Alzheimer’s patients, revealing that they increase early in the disease. Additional experiments in Alzheimer’s mouse models suggested that DKK3 secretion rise before amyloid-β plaques form, with the protein then accumulating in abnormal neuronal structures present in the surroundings of these toxic deposits. Martin-Flores, Podpolny et al. then examined the impact of DKK3 on the Wnt pathway, and ultimately, on the balance between synapses that control neuronal activity. These experiments showed that elevated DKK3 levels are linked to a loss of synapses which are excitatory, with a concomitant increase in those that are inhibitory. Crucially, reducing DKK3 levels in a mouse model of Alzheimer’s restored this synaptic balance and improved memory, highlighting DKK3 as a potential driver of cognitive impairment. Overall, these findings help to refine our understanding of the molecular mechanisms that contribute to synaptic impairment in Alzheimer’s disease. They may also be relevant for researchers studying other conditions that involve aberrant activity of the Wnt pathway, such as cancer.
Autres résumés
Type: plain-language-summary
(eng)
Alzheimer’s disease is the most common form of dementia worldwide. The cognitive decline typically observed in this condition is associated with the weakening and eventually the loss of synapses, the structures that allow neurons to communicate. Increasing evidence points to this deterioration being linked to deficiency in the Wnt signalling pathway, a cascade of molecular events crucial for brain function and development. The DKK protein family helps to tightly regulate the Wnt pathway by dampening its activity. Previous work suggests that DKK proteins could also be connected to Alzheimer’s disease. For example, an elevated amount of DKK1 leads to synapse and memory defects in mice, while brain production of DKK1 is increased in individuals with late Alzheimer’s. More recent studies show high levels of another DKK protein, DKK3, in Alzheimer’s patients. This protein is also present in the harmful amyloid-β aggregates, named ‘plaques’, that typically form in the brain in this condition. Despite these findings, how DKK3 participates in synaptic health remains unclear. To address this question, Martin-Flores, Podpolny et al. tracked DKK3 levels in the brains of Alzheimer’s patients, revealing that they increase early in the disease. Additional experiments in Alzheimer’s mouse models suggested that DKK3 secretion rise before amyloid-β plaques form, with the protein then accumulating in abnormal neuronal structures present in the surroundings of these toxic deposits. Martin-Flores, Podpolny et al. then examined the impact of DKK3 on the Wnt pathway, and ultimately, on the balance between synapses that control neuronal activity. These experiments showed that elevated DKK3 levels are linked to a loss of synapses which are excitatory, with a concomitant increase in those that are inhibitory. Crucially, reducing DKK3 levels in a mouse model of Alzheimer’s restored this synaptic balance and improved memory, highlighting DKK3 as a potential driver of cognitive impairment. Overall, these findings help to refine our understanding of the molecular mechanisms that contribute to synaptic impairment in Alzheimer’s disease. They may also be relevant for researchers studying other conditions that involve aberrant activity of the Wnt pathway, such as cancer.
Identifiants
pubmed: 38285009
doi: 10.7554/eLife.89453
pii: 89453
doi:
pii:
Substances chimiques
Dkk3 protein, mouse
0
Adaptor Proteins, Signal Transducing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/X010589/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S012125/1
Pays : United Kingdom
Organisme : Alzheimer's Society
ID : AS-PG-17-006
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T033371/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M024083/1
Pays : United Kingdom
Informations de copyright
© 2023, Martin Flores, Podpolny et al.
Déclaration de conflit d'intérêts
NM, MP, FM, IW, KC, DI, GL, VE, PS No competing interests declared
Références
Front Synaptic Neurosci. 2021 Jun 03;13:670467
pubmed: 34149390
Circulation. 2017 Sep 12;136(11):1022-1036
pubmed: 28674110
J Biol Chem. 2003 Sep 26;278(39):37024-31
pubmed: 12857724
Cell Rep. 2018 May 15;23(7):2039-2055
pubmed: 29768203
Eur J Neurosci. 1999 Oct;11(10):3512-6
pubmed: 10564359
J Neurosci. 2004 Jun 30;24(26):6021-7
pubmed: 15229249
Neurobiol Aging. 2013 Jun;34(6):1709.e9-18
pubmed: 23218566
Nat Commun. 2015 Jul 16;6:7364
pubmed: 26179122
Gene. 1999 Oct 1;238(2):301-13
pubmed: 10570958
J Clin Invest. 2014 Jul;124(7):3263-73
pubmed: 24911145
Cell. 2017 Jun 1;169(6):985-999
pubmed: 28575679
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
J Neurosci. 2000 Jun 1;20(11):4050-8
pubmed: 10818140
Mol Psychiatry. 2014 Jan;19(1):88-98
pubmed: 23164821
J Neurochem. 2010 Mar;112(6):1539-51
pubmed: 20050968
EMBO Rep. 2023 Aug 3;24(8):e57499
pubmed: 37401859
Bioinformatics. 2012 Jun 1;28(11):1530-2
pubmed: 22539670
Nat Commun. 2014 Oct 16;5:4992
pubmed: 25318560
Neurosci Lett. 2004 Aug 19;366(3):320-5
pubmed: 15288443
Aging Cell. 2022 Feb;21(2):e13549
pubmed: 35026048
Neurology. 1991 Apr;41(4):479-86
pubmed: 2011243
Alzheimers Dement. 2018 Mar;14(3):306-317
pubmed: 29055813
J Neurosci. 2014 Sep 3;34(36):11929-47
pubmed: 25186741
J Alzheimers Dis. 2017;60(2):733-746
pubmed: 28922151
Diabetes. 2003 Mar;52(3):588-95
pubmed: 12606497
Acta Neuropathol Commun. 2019 Dec 20;7(1):214
pubmed: 31862015
Mol Psychiatry. 2022 Jul;27(7):3024-3033
pubmed: 35296808
Front Cell Neurosci. 2014 Mar 04;8:64
pubmed: 24624058
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
J Neurosci. 2011 May 4;31(18):6627-38
pubmed: 21543591
Nat Neurosci. 2022 Feb;25(2):213-225
pubmed: 35115731
Cell Rep. 2022 Dec 13;41(11):111817
pubmed: 36516756
Am J Pathol. 2000 Dec;157(6):2003-10
pubmed: 11106573
J Neurochem. 2015 Sep;134(6):1152-62
pubmed: 26119087
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10732-7
pubmed: 21670302
J Vis Exp. 2017 Oct 6;(128):
pubmed: 29053699
Science. 2016 May 6;352(6286):712-716
pubmed: 27033548
Alzheimers Dement. 2019 Mar;15(3):429-440
pubmed: 30502339
Front Immunol. 2015 Feb 24;6:78
pubmed: 25759692
Genes Dev. 2007 Feb 15;21(4):465-80
pubmed: 17322405
Neuron. 2014 Oct 1;84(1):63-77
pubmed: 25242217
Nature. 2002 Apr 4;416(6880):535-9
pubmed: 11932745
Curr Biol. 2016 Oct 10;26(19):2551-2561
pubmed: 27593374
Mol Cell Biol. 2006 Mar;26(6):2317-26
pubmed: 16508007
Brain. 2012 Jul;135(Pt 7):2155-68
pubmed: 22637583
Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23527-23538
pubmed: 32907943
J Vis Exp. 2011 Jul 26;(53):
pubmed: 21841757
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9434-9
pubmed: 17517621
Acta Neuropathol. 2006 Oct;112(4):389-404
pubmed: 16906426
Neuro Oncol. 2008 Jun;10(3):244-53
pubmed: 18443132
Nat Rev Mol Cell Biol. 2012 Dec;13(12):767-79
pubmed: 23151663
J Neurosci. 2009 Feb 18;29(7):1977-86
pubmed: 19228952
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20504-9
pubmed: 19918059
Sci Data. 2018 Sep 11;5:180185
pubmed: 30204156
Acta Neuropathol. 2017 Jun;133(6):933-954
pubmed: 28258398
Biophys J. 1997 Jul;73(1):220-9
pubmed: 9199786
Commun Biol. 2019 Feb 4;2:43
pubmed: 30729181
Nat Neurosci. 2014 May;17(5):661-3
pubmed: 24728269
Sci Data. 2016 Oct 11;3:160089
pubmed: 27727239
Curr Opin Neurobiol. 2018 Dec;53:90-95
pubmed: 29975877
Cell Rep. 2018 Apr 24;23(4):1060-1071
pubmed: 29694885
Neuropathol Appl Neurobiol. 2007 Feb;33(1):43-55
pubmed: 17239007
J Neurosci. 2012 Mar 7;32(10):3492-8
pubmed: 22399772
Bioorg Med Chem Lett. 2012 Feb 1;22(3):1433-8
pubmed: 22244937
Oncogene. 2006 Dec 4;25(57):7469-81
pubmed: 17143291
Sci Data. 2018 Aug 07;5:180142
pubmed: 30084846
Cancer Res. 2005 Nov 1;65(21):9617-22
pubmed: 16266978
Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006338
pubmed: 22762015
Neuron. 2008 Dec 26;60(6):1010-21
pubmed: 19109908
Sci Adv. 2023 Jan 13;9(2):eabo7421
pubmed: 36638182